Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Menu Back to Poster-Presentations-Details

P206: SARS-CoV-2 Viral Levels and Antibody Response in Mildly Symptomatic and Asymptomatic Participants

Poster Presenter

      Sabina Paglialunga

      • Director, Scientific Affairs
      • Celerion
        United States


More than 2 years into the COVID-19 pandemic, there is still limited data available on viral levels in mildly symptomatic and asymptomatic infected individuals. This observational trial evaluated SARS-CoV-2 viral kinetics and antibody response in otherwise healthy adults positive for COVID-19.


Participants detected for SARS-CoV-2 during routine screening were enrolled in an 8-week study. Ultrasensitive saliva and extraction-free nasopharyngeal SARS-CoV-2 PCR assays were validated for paired specimen analysis, and immune response was evaluated with a serum spike protein antibody assay.


The nasopharyngeal and saliva PCR assays were established using 2019-nCoV selected from nucleocapsid gene and human RNase P gene prime-probe sets. Both methods demonstrated good precision and reproducibility, with 100% reproducibility established for Within-Assay, Between-Assay and Between-Operators. The limit of quantification ranged from 0.5-10,000 genome copies/µL. When comparing PCR results against a commercial diagnostic test, our ultrasensitive assay demonstrated excellent performance determined by an area-under the receiver operator curve (AUROC) of 93%. Assay sensitivity and positive predictive value were 90% and 86%, respectively. The assays were applied in a clinical observational trial that enrolled 30 participants (11 males / 19 females). Twenty percent were completely asymptomatic, while the remaining reported mild symptoms of persistent cough, congestion or runny nose, new loss of taste and/or smell, and brain fog. Nonlinear regression modeling of asymptomatic data demonstrated lower SARS-CoV-2 RNA levels throughout the study compared to symptomatic counterparts for both nasopharyngeal (p=0.004) and saliva (p<0.0001) samples. On the other hand, antibody response was similar between the two groups. Interestingly, when subdividing symptomatic subjects by the number of symptoms experienced, participants reporting >5 symptoms displayed the highest SARS-CoV-2 RNA levels accompanied by the lowest antibody response.


We validated sensitive and robust assays to detect and monitor SARS-CoV-2 viral levels from nasopharyngeal and saliva samples. These methods demonstrated excellent performance and positive predictive value against a commercial diagnostic test. Furthermore, our assays were able to detect differences in the viral kinetics between asymptomatic and mildly symptomatic COVID-19 infected subjects. Overall, these findings demonstrate that higher viral levels are associated with a greater number of COVID-19 symptoms, and may suggest a certain viral level threshold is needed to induce symptoms in otherwise healthy adults. As more variants of the virus emerge, the relationship between viral load and symptoms warrants further exploration.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.